A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart Disease

New England Journal of Medicine

Volumn 313, Issue 17, 1985, Pages 1044-1049

  Stampfer, Meir J ^a   Willett, Walter C ^a   Colditz, Graham A ^a   Rosner, Bernard ^a   Speizer, Frank E ^a   Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; TOBACCO SMOKE;

CARDIOVASCULAR SYSTEM; DRUG THERAPY; ENDOCRINE SYSTEM; FEMALE; HEART; HEART INFARCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SMOKING; THERAPY;

EID: 0022379663     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198510243131703     Document Type: Article

References (66)

1. Marmorston J, Moore FJ, Hopkins CE, Kuzma OT, Weiner J. Clinical studies of long-term estrogen therapy in men with myocardial infarction. Proc Soc Exp Biol Med 1962; 110: 400–8.
2. Stamler J, Pick R, Katz LN, et al. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA 1963; 183: 632–8.
3. Robinson RW, Cohen WD, Higano N. Estrogen replacement therapy in women with coronary atherosclerosis. Ann Intern Med 1958; 48: 95–101.
4. The Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA 1970; 214: 1303–13.
5. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973; 226: 652–7.
6. Jick H, Dinan B, Rothman KJ. Noncontraceptive estrogens and nonfatal myocardial infarction. JAMA 1978; 239: 1407–8.
7. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women: role of estrogens and other factors. JAMA 1978; 240: 2548–52.
8. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858–60.
9. Bush T, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program follow-up study. JAMA 1983; 249: 903–6.
10. Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985; 65: 441–6.
11. Hennekens CH, Speizer FE, Rosner B, Bain CJ, Belanger C, Peto R. Use of permanent hair dyes and cancer among registered nurses. Lancet 1979; 1: 1390–3.
12. World Health Organization. IHD registers: report of the fifth working group. Copenhagen: World Health Organization, 1971.
13. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47–51.
14. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117: 651–8.
15. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Washington, D.C.: Public Health Service, 1979. (NIH publication no. 79–1649).
16. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 226–35.
17. Cox D.R., Regression models and life-tables. J R Stat Soc (B) 1972; 34: 187–220.
18. Colditz GC, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of disease in women. Am J Epidemiol (in press).
19. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1980; 136: 859–71.
20. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in post-menopausal women. N Engl J Med 1976; 294: 1256–9.
21. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS. Noncontraceptive estrogens and myocardial infarction in young women. JAMA 1980; 244: 339–42.
22. Szklo M, Tonascia J, Gordis L, Bloom I. Estrogen use and myocardial infarction risk: a case–control study. Prev Med 1984; 13: 510–6.
23. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case–control study. Br Med J 1981; 282: 1277–8.
24. Weiss NS, Ure C, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195–8.
25. Pfeffer RI, Whipple GH, Kurosaki TT, Chapman JM. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 1978; 107: 479–87.
26. Bain C, Willett W, Hennekens CH, Rosner B, Belanger C, Speizer FE. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981; 64: 42–46.
27. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979; 133: 525–36.
28. Burch JC, Byrd BF, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol 1974; 118: 778–82.
29. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978; 89: 157–61.
30. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150–4.
31. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74–79.
32. Bush T, Cowan L, Barrett-Connor E, et al. Estrogen use and cardiovascular disease mortality: the Lipid Research Clinics follow-up study. Am J Epidemiol 1983; 118: 450. abstract.
33. Criqui M, Suarez L, Barrett-Connor E, Wingard D, Garland C. Postmenopausal estrogen use and mortality: a prospective study. Am J Epidemiol 1984; 120: 466. abstract.
34. Paganini-Hill A, Ross RK, Henderson BE. Protection from acute myocardial infarction among users of estrogen replacement therapy. Am J Epidemiol 1985; 122: 512. abstract.
35. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use and cardiovascular morbidity: the Framingham study. CVD Epidemiol News 1984; 35: 35. abstract.
36. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women: the Framingham study. Ann Intern Med 1977; 87: 393–7.
37. Barrett-Connor E, Brown WV, Turner J, Austin M, Criqui MH. Heart disease risk factors and hormone use in postmenopausal women. JAMA 1979; 241: 2167–9.
38. Wallace RB, Hoover J, Barrett-Connor E, et al. Altered plasma lipid and lipoprotein levels associated with oral contraceptive and oestrogen use: report from the Medications Working Group of the Lipid Research Clinics Program. Lancet 1979; 2: 111–5.
39. Wallentin L, Larsson-Cohn U. Metabolic and hormonal effects of postmenopausal oestrogen replacement treatment. II. Plasma lipids. Acta Endocrinol (Copenh) 1977; 86: 597–607.
40. Tikkanen MJ, Nikkila EA, Vartiainen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet 1978; 2: 490–1.
41. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 16–19.
42. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977; 62: 707–14.
43. Fischer GM. In vivo effects of estradiol on collagen and elastin dynamics in rat aorta. Endocrinology 1972; 91: 1227–32.
44. Fischer GM, Cherian K, Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis: inhibition by contraceptive steroids. Atherosclerosis 1981; 39: 463–7.
45. Kishi Y, Numano F. A study of the mechanism of estrogen as an antiathero-sclerotic: the inhibitory effect of estrogen on A23187-induced contraction of the aortic wall. Mech aging Dev 1982; 18: 115–23.
46. Chang W.-C., Nakao J, Orimo H, Murota S.-I. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochim Biophys Acta 1980; 620: 472–82.
47. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164–7.
48. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167–70.
49. Antunes CMF, Stolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use: report of a large case–control study. N Engl J Med 1979; 300: 9–13.
50. Hulka BS, Kaufman DG, Fowler WC Jr, Grimson RC, Greenberg BG. Predominance of early endometrial cancers after long-term estrogen use. JAMA 1980; 244: 2419–22.
51. Weiss NS. Noncontraceptive estrogens and abnormalities of endometrial proliferation. Ann Intern Med 1978; 88: 410–2.
52. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294: 1262–7.
53. Silverberg E. Cancer statistics, 1984. CA 1984; 34: 7–23.
54. Sartwell PE, Arthes FG, Tonascia JA. Exogenous hormones, reproductive history, and breast cancer. JNCI 1977; 59: 1589–92.
55. Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. JNCI 1981; 67: 327–33.
56. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983; 62: 435–43.
57. Buring J, Speizer F, Lipnick R, et al. A prospective cohort study of postmenopausal female hormone use and risk of breast cancer. Am J Epidemiol 1983; 118: 416. abstract.
58. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy: a report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974; 290: 15–9.
59. Lauritzen C. The female climacteric syndrome: significance, problems, treatment. Acta Obstet Gynecol Scand [Suppl] 1976; 51: 47–61.
60. Riggs BL, Seeman E, Hodgson SF, Taves D.R., O'Fallon WM. Effects of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982; 306: 446–50.
61. Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983; 309: 1405–7.
62. Riggs BL, Jowsey J, Goldsmith RS, Kelly PJ, Hoffman DL, Arnaud CD. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest 1972; 51: 1659–63.
63. Weinstein MC. Estrogen use in postmenopausal women — costs, risks, and benefits. N Engl J Med 1980; 303: 308–16.
64. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983; 38: 445–55.
65. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305: 1599–605.
66. Hirvonen E, Mälkönen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304: 560–3.